Kidney Diseases – Talk Bio

Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart

2 months ago talkbio0Tagged Blood, Infrequent, Kidney Diseases, MASP-3 Inhibitor, Novo Nordisk, Omeros, Zaltenibart

Novo Nordisk; Omeros; Zaltenibart; MASP-3 Inhibitor; Rare Blood and Kidney Disorders

Apellis’ Empaveli Gains FDA Approval for Broad C3 Glomerulopathy Use, Setting Up Competition with Novartis’ Fabhalta

5 months ago talkbio0Tagged Apellis, Approved, C3 glomerulopathy, Empaveli, Fabhalta, Iptacopan, Kidney Diseases, membranoproliferative glomerulonephritis, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Apellis; Empaveli; FDA approval; C3 glomerulopathy; primary immune complex membranoproliferative glomerulonephritis; Novartis; Fabhalta; pegcetacoplan; iptacopan; proteinuria; kidney disease

Otsuka’s Phase 3 IgAN Win with Sibeprenlimab Shakes Vera’s Stock

6 months ago talkbio0Tagged IGA Glomerulonephritis, Kidney Diseases, Otsuka, Priority Review, Proteinuria, Sibeprenlimab, stock drop, United States Food and Drug Administration, UPCR, vera

Otsuka; sibeprenlimab; IgA nephropathy; phase 3 trial; proteinuria reduction; Vera Therapeutics; stock drop; kidney disease; UPCR; FDA Priority Review

Novartis to buy Regulus Therapeutics for up to $1.7B

8 months ago talkbio0Tagged Acquisition (action), Goldcrest, Kidney Diseases, Novartis

Goldcrest, Novartis, Acquisition (action), Kidney Diseases

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis

9 months ago talkbio0Tagged Apellis, Approved, C3 G, Fabhalta, Kidney Diseases, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

11 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

11 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs

1 year ago talkbio0Tagged amsacrine/azacitidine/etoposide, APOL1 gene, Chronic Kidney Diseases, clinical-stage programs, Kidney Diseases, MZE782, MZE829, Precision Medicine, Series

Maze Therapeutics, Series D funding, kidney disease, clinical-stage programs, precision medicine, APOL1 kidney disease, chronic kidney disease, MZE829, MZE782.